Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae477 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Essy Mozaffari und 10 weiteren Autor:innen. Beteiligte Einrichtung: Global Medical Affairs, Gilead Sciences, Foster City, California, USA. Hauptthemen laut MEDLINE: Dexamethasone, COVID-19 Drug Treatment, Adenosine Monophosphate, Alanine. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Inc.
Abstract (Originalsprache)
Background
Treatment guidelines were developed early in the pandemic when much about coronavirus disease 2019 (COVID-19) was unknown. Given the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), real-world data can provide clinicians with updated information. The objective of this analysis was to assess mortality risk in patients hospitalized for COVID-19 during the Omicron period receiving remdesivir + dexamethasone versus dexamethasone alone.
Methods
A large, multicenter US hospital database was used to identify adult patients hospitalized with a primary discharge diagnosis of COVID-19 flagged as “present-on-admission” and treated with remdesivir + dexamethasone or dexamethasone alone between December 2021 and April 2023. Patients were matched using 1:1 propensity score matching and stratified by baseline oxygen requirements. Cox proportional hazards model was used to assess time to 14- and 28-day in-hospital all-cause mortality.
Results
A total of 33 037 patients were matched, with most patients ≥65 years old (72%), White (78%), and non-Hispanic (84%). Remdesivir + dexamethasone was associated with lower mortality risk versus dexamethasone alone across all baseline oxygen requirements at 14-days (no supplemental oxygen charges: adjusted hazard ratio [95% confidence interval {CI}]: 0.79 [.72–.87], low flow oxygen: 0.70 [.64–.77], high flow oxygen/non-invasive ventilation: 0.69 [.62–.76], invasive mechanical ventilation/extracorporeal membrane oxygen (IMV/ECMO): 0.78 [.64–.94]), with similar results at 28-days.
Conclusions
Remdesivir + dexamethasone was associated with a significant reduction in 14- and 28-day mortality compared to dexamethasone alone in patients hospitalized for COVID-19 across all levels of baseline respiratory support, including IMV/ECMO. However, the use of remdesivir + dexamethasone still has low clinical practice uptake. In addition, these data suggest a need to update the existing guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Global Medical Affairs, Gilead Sciences, Foster City, California, USA.
- Evidence & Access, Certara, New York, New York, USA.
- Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA.
- Baylor Scott & White Heart and Vascular Hospital, Dallas, Texas, USA.
- Baylor Scott & White The Heart Hospital, Plano, Texas, USA.
- Baylor Scott & White Research Institute, Dallas, Texas, USA.
ORCID-Profile: Aastha Chandak, Robert L Gottlieb, Chidinma Chima-Melton, Mark Berry, Thomas Oppelt, Alpesh N Amin, Andre C Kalil
Förderung
- Gilead Sciences, Inc
Zitieren
APA
Mozaffari, E., Chandak, A., Gottlieb, R. L., Chima-Melton, C., Berry, M., Oppelt, T., Okulicz, J. F., Amin, A. N., Welte, T., Sax, P. E., & Kalil, A. C. (2025). Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae477
Vancouver
Mozaffari E, Chandak A, Gottlieb RL, Chima-Melton C, Berry M, Oppelt T, et al. Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae477
BibTeX
@article{Mozaffari2025,
author = {Mozaffari, Essy and Chandak, Aastha and Gottlieb, Robert L and Chima-Melton, Chidinma and Berry, Mark and Oppelt, Thomas and Okulicz, Jason F and Amin, Alpesh N and Welte, Tobias and Sax, Paul E and Kalil, Andre C},
title = {Lower Mortality Risk Associated With Remdesivir + Dexamethasone Versus Dexamethasone Alone for the Treatment of Patients Hospitalized for COVID-19},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae477}
}
EUVIMED